13F-HR filed by Knoll Capital Management, LLC
Knoll Capital Management, LLC filed this 13F-HR for the quarter ended 2015-12-31, filed 2016-02-17, with 21 holding rows worth $269,729,000.
- Accession
- 0001144204-16-083000
- Filer
- CIK 1325083
- Filed
- 2016-02-17
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2015
A holdings report, 21 entries on the cover page, a total value of $269,729,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $269,729,000 with VALUE read as thousands by filing date, 13F file number 028-11424. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| MEDIVATION INC | 58501N101 | COM | 4,397,838 | $212,591,000 | thousands by filing date | |
| Ampio Pharmaceuticals | 03209T109 | COM | 3,388,322 | $11,859,000 | thousands by filing date | |
| SYNTHETIC BIOLOGICS INC | 87164U102 | COM | 3,734,149 | $8,551,000 | thousands by filing date | |
| Alcobra Ltd | M2239P109 | SHS | 1,115,315 | $7,004,000 | thousands by filing date | |
| CEMPRA INC | 15130J109 | COM | 180,800 | $5,628,000 | thousands by filing date | |
| ABEONA THERAPEUTICS INC | 00289Y107 | COM | 1,359,767 | $4,569,000 | thousands by filing date | |
| CORBUS PHARMACEUTICALS HLDGS | 21833P103 | COM | 2,563,925 | $4,230,000 | thousands by filing date | |
| NEWLINK GENETICS CORP | 651511107 | COM | 102,437 | $3,728,000 | thousands by filing date | |
| ADVAXIS INC | 007624208 | COM NEW | 275,000 | $2,767,000 | thousands by filing date | |
| Vascular Biologics LTD | 96883109 | COM | 333,332 | $1,753,000 | thousands by filing date | The CUSIP as filed is malformed. |
| BIOBLAST PHARMA LTD | M20156101 | SHS | 338,110 | $1,312,000 | thousands by filing date | |
| OHR PHARMACEUTICAL INC | 67778H200 | COMMON STOCK | 205,000 | $1,259,000 | thousands by filing date | |
| KERYX BIOPHARMACEUTICALS | 492515101 | COMMON STOCK | 200,000 | $1,010,000 | thousands by filing date | |
| ALDEYRA THERAPEUTICS INC | 01438T106 | COM | 135,800 | $921,000 | thousands by filing date | |
| ADVAXIS INC | 007624117 | *W EXP 10/22/201 | 112,500 | $798,000 | thousands by filing date | |
| CALADRIUS BIOSCIENCES INC | 128058104 | Cmn | 555,781 | $600,000 | thousands by filing date | |
| GALMED PHARMACEUTICALS LTD | M47238106 | SHS | 65,000 | $495,000 | thousands by filing date | |
| CHAMPIONS ONCOLOGY INC | 15870P307 | COM NEW | 111,111 | $397,000 | thousands by filing date | |
| EVOKE PHARMA INC | 30049G104 | COM | 55,660 | $184,000 | thousands by filing date | |
| Adobe Systems Inc | 98979H103 | COM | 18,600 | $42,000 | thousands by filing date | |
| APTOSE BIOSCIENCES INC COM | 03835T200 | Stock | 11,933 | $31,000 | thousands by filing date |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001144204-16-083000 | this filing | 2016-02-17 | acceptance time not in the bulk data set |